12 Month Price Forecast For NOVT
Distance to NOVT Price Forecasts
NOVT Price Momentum
๐ค Considering Novanta (NOVT)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 7:20 PM UTC
NOVT Analyst Ratings & Price Targets
Based on our analysis of 3 Wall Street analysts, NOVT has a consensus that is neutral. The median price target is $169.00, with forecasts ranging from $138.34 to $187.00. Currently, there are 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With NOVT currently trading at $148.84, the median price forecast suggests a 13.5% upside. The most optimistic forecast comes from at , projecting a 25.6% upside, while at provides the most conservative target, suggesting a -7.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NOVT Analyst Consensus
NOVT Price Target Range
Latest NOVT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NOVT.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 6, 2024 | Baird | Robert Mason | Neutral | Maintains | $169.00 |
Aug 7, 2024 | Baird | Robert Mason | Neutral | Maintains | $175.00 |
May 11, 2023 | Baird | Robert Mason | Neutral | Maintains | $161.00 |
May 11, 2022 | William Blair | Brian Drab | Outperform | Upgrade | $0.00 |
Nov 13, 2020 | Berenberg | Hold | Initiates | $0.00 | |
May 13, 2020 | Baird | Neutral | Maintains | $90.00 | |
Feb 28, 2019 | Baird | Neutral | Maintains | $81.00 | |
May 9, 2018 | Baird | Neutral | Downgrade | $0.00 | |
Feb 27, 2018 | William Blair | Outperform | Initiates | $0.00 | |
Dec 8, 2017 | Baird | Outperform | Initiates | $0.00 |
Stocks Similar to Novanta Inc
The following stocks are similar to Novanta based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Novanta Inc (NOVT) Financial Data
Novanta Inc has a market capitalization of $5.35B with a P/E ratio of 89.1x. The company generates $922.75M in trailing twelve-month revenue with a 6.5% profit margin.
Revenue growth is +10.3% quarter-over-quarter, while maintaining an operating margin of +14.3% and return on equity of +8.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Novanta Inc (NOVT) Company Overview
About Novanta Inc
Provides precision medicine and automation solutions.
Novanta Inc. operates through three main segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. The company generates revenue by selling a diverse range of high-tech products including lasers, medical devices, and automation technologies through both direct sales and distributors under various recognized brands.
Founded in 1968 and headquartered in Bedford, Massachusetts, Novanta Inc. has a strong international presence and focuses on innovative solutions in the medical and industrial sectors. The company was formerly known as GSI Group, Inc. and rebranded in May 2016.
Company Information
Sector
Technology
Industry
Scientific & Technical Instruments
Employees
2,900
CEO
Mr. Matthijs Glastra
Country
United States
IPO Year
1999
Website
www.novanta.comNovanta Inc (NOVT) Latest News & Analysis
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 25, 2025
9 days agoNovanta Inc. (Nasdaq: NOVT) will release its Q4 and full year 2024 results on February 25, 2025, and host a conference call at 10:00 a.m. ET. Access details provided.
Novanta Inc.'s upcoming earnings release and conference call may impact stock prices, providing insights into financial performance and future growth potential, critical for investment decisions.
Novanta Inc. will participate in the CJS Securities 25th Annual New Ideas for the New Year Investor Conference on January 14, 2025, held virtually.
Novanta Inc.'s participation in a prominent investor conference signals potential growth opportunities and investor interest, impacting stock performance and market perception.
Novanta to Present at the J.P. Morgan 43rd Annual Healthcare Conference on Monday, January 13, 2025
1 month agoNovanta Inc. (Nasdaq: NOVT) will present at the J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco, featuring CEO Matthijs Glastra and CFO Robert Buckley.
Novanta's presentation at a major healthcare conference may signal strategic developments, influencing investor confidence and potential stock movement in the medical technology sector.
Novanta Inc. (NOVT) Q3 2024 Earnings Call Transcript
3 months agoNovanta Inc. will hold its Q3 2024 results conference call on November 5, 2024, at 10:00 AM ET, featuring executives including CEO Matthijs Glastra and CFO Robert Buckley.
Novanta Inc.'s Q3 2024 results call could reveal insights into financial performance and future guidance, influencing stock valuation and investor sentiment.
Novanta Inc. reported Q3 2024 revenue of $244.4M, up from $221.5M in Q3 2023. Operating income increased to $32.6M, while net income decreased to $19.2M, with diluted EPS not specified.
Novanta's Q3 2024 revenue growth indicates strong demand, but a dip in net income and EPS suggests potential profitability concerns, impacting investor sentiment and valuation.
Novanta (NOVT) Q3 Earnings Miss Estimates
3 months agoNovanta (NOVT) reported Q3 earnings of $0.85 per share, missing the consensus estimate of $0.86. Earnings remained unchanged from $0.85 per share in the same quarter last year.
Novanta's earnings miss may signal weaker operational performance, potentially affecting investor confidence and stock valuation. Consistent earnings could impact future growth expectations.
Frequently Asked Questions About NOVT Stock
What is Novanta Inc's (NOVT) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Novanta Inc (NOVT) has a median price target of $169.00. The highest price target is $187.00 and the lowest is $138.34.
Is NOVT stock a good investment in 2025?
According to current analyst ratings, NOVT has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $148.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for NOVT stock?
Wall Street analysts predict NOVT stock could reach $169.00 in the next 12 months. This represents a 13.5% increase from the current price of $148.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Novanta Inc's business model?
Novanta Inc. operates through three main segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. The company generates revenue by selling a diverse range of high-tech products including lasers, medical devices, and automation technologies through both direct sales and distributors under various recognized brands.
What is the highest forecasted price for NOVT Novanta Inc?
The highest price target for NOVT is $187.00 from at , which represents a 25.6% increase from the current price of $148.84.
What is the lowest forecasted price for NOVT Novanta Inc?
The lowest price target for NOVT is $138.34 from at , which represents a -7.1% decrease from the current price of $148.84.
What is the overall NOVT consensus from analysts for Novanta Inc?
The overall analyst consensus for NOVT is neutral. Out of 3 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $169.00.
How accurate are NOVT stock price projections?
Stock price projections, including those for Novanta Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.